吉西他滨联合多西他赛一线治疗复发/转移性腹膜后平滑肌肉瘤  

Combination of gemcitabine and docetaxel as first line chemotherapy in patients with recurrent/metastatic retroperitoneal leiomyosarcoma

作　　者：李倩[1] 周宇红[1] 王妍[1] 李泓[1] 申峰[1] 刘天舒[1] 金文[1] 庄荣源[1] 

机构地区：[1]复旦大学附属中山医院肿瘤内科,上海200032

出　　处：《肿瘤》2015年第1期65-71,共7页Tumor

摘　　要：目的：观察GT（吉西他滨联合多西他赛）方案一线治疗复发/转移性腹膜后平滑肌肉瘤（retroperitoneal leiomyosarcoma,RLMS）患者的疗效和不良反应。方法：采用GT方案治疗12例复发/转移性RLMS患者：吉西他滨900mg/m^2静脉滴注第1天和第8天,多西他赛75 mg/m^2静脉滴注第8天;每21 d为1个化疗周期。观察疗效和不良反应。结果：12例可评估患者共完成49个化疗周期,中位化疗周期数为3个（范围：1～8个）。2例（16.7%）患者为部分缓解,4例（33.3%）为疾病稳定,6例（50.0%）为疾病进展,疾病控制率达50.0%。中位无进展生存期为4.0个月（95%可信区间：2.9～5.1个月）,中位生存期为18.0个月（95%可信区间：5.4～30.6个月）。最常见的不良反应为骨髓抑制,其中3/4级不良反应主要为白细胞/中性粒细胞减少4例（33.3%）、血小板减少1例（8.3%）、贫血1例（8.3%）。无因不良反应导致退组或致死病例。结论：GT方案一线治疗复发/转移性原发RLMS的疗效肯定且耐受性良好。Objective：To evaluate the efficacy and toxicity of CT regimen（gemcitabine and docetaxel） in patients with current/metastatic retroperitoneal leiomyosarcoma（RLMS） as first line therapy.Methods：Twelve eligible patients were treated with CT regimen（gemcitabine 900 mg/m^2 d 1 and d 8,combined with docetaxel 75 mg/m^2 d 8;repeated every 21 days）.Response and toxicity were evaluated.Results：Twelve patients were enrolled and completed at least 1 cycle and received a total of 49 cycles[median：3 cycles（range：l-8）]of CT regimen.All patients were evaluable for efficacy：no complete response,2 patients（16.7%）attained partial response,4 patients（33.3%） were stable disease,6 patients（50.0%） were of progressive disease.The disease control rate was 50.0%.The median progression-free survival and the median survival time were 4.0 months（95%confidence internal：2.9-5.1） and 1 8.0months（95%confidence internal：5.4-30.6）,respectively.The most common toxicity was marrow suppression.The 3/4 grade toxicities included leukopenia/neutropenia in 4（33.3%）patients,thrombopenia in 1（8.3%）,and anemina in 1（8.3%）.No patients died or withdrew due to toxicity.Conclusion：GT regime as a first line treatment for current/metastatic RLMS is highly active and well tolerated.

关 键 词：平滑肌肉瘤 腹膜后 复发 转移 抗肿瘤联合化疗方案 吉西他滨 多西他赛 

分 类 号：R738.6[医药卫生—肿瘤]